ATXS
Astria Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
consensus rating "Buy"
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ATXS
Astria Therapeutics, Inc.
A company that develops novel therapeutics for the rare and niche allergic and immunological diseases
75 State Street, Suite 1400, Boston, Massachusetts 02109
--
Astria Therapeutics, Inc., was founded in Delaware on June 26, 2008 and is headquartered in Cambridge, Massachusetts.
The company is a biopharmaceutical company focused on the discovery, development and commercialization of new therapies. The company's mission is to bring hope to patients and families affected by rare and niche allergic and immune diseases through life-changing therapies. The company's lead product candidate is STAR-0215, a potentially best-in-class monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. Based on the data generated so far and the existing HAE treatment profile, STAR-0215 has the potential to be the most patient-friendly chronic treatment for HAE.
Company Financials
EPS
ATXS has released its 2024 Q4 earnings. EPS was reported at -0.44, versus the expected -0.43, missing expectations. The chart below visualizes how ATXS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
